Alzheon Board of Directors2018-08-06T06:42:19+00:00

Board of Directors

Jean-Pierre Garnier AlzheonChairman of Idorsia
Former Chairman of Actelion
Former CEO of GlaxoSmithKline

Jean-Pierre Garnier, Ph.D. has served on our board of directors since December 2015. Dr. Garnier also currently serves on the boards of directors of United Technology Corporation, Idorsia Ltd. and Radius Health, Inc., and previously served on the boards of directors of Renault S.A. and Actelion Ltd. Dr. Garnier has also served as an Operating Partner at Advent International, a private equity firm, since 2013. Dr. Garnier has served on the Advisory Board of the Newman’s Own Foundation since 2011 and on the Advisory Board of The Max Planck Institute since 2011. From 2008 to 2010, Dr. Garnier served as the Chief Executive officer of Pierre Fabre Laboratories, a pharmaceutical company, and from 2000 to 2008, he served as the Chief Executive Officer of GlaxoSmithKline, Inc., a global pharmaceutical company.

Dr. Garnier received his M.Sc. in pharmaceutical science and Ph.D. in pharmacology from Louis Pasteur University in France and his MBA from Stanford University.

We believe Dr. Garnier is qualified to serve as a member of our board of directors because of his significant business experience, expertise in the life science industry, membership on various boards of directors and previous leadership and management roles.

Neil Flanzraich AlzheonExecutive Chairman of Cantex Pharmaceuticals, Inc.
Former CEO of Cantex Pharmaceuticals, Inc.

Mr. Flanzraich brings to Alzheon more than 30 years of executive leadership, operations and legal experience with pharmaceutical and life sciences companies.  Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.

Mr. Flanzraich is the Executive Chairman of Cantex Pharmaceuticals, Inc., a privately-owned biotech company, which is developing drugs for cancer.  Previously, he was Cantex’s Chief Executive Officer.  Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company, for over seven years, prior to its sale in 2006 to TEVA Pharmaceutical Industries, Ltd. for an enterprise value of $10 billion.  Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm.  Previously Mr. Flanzraich worked at Syntex Corporation, an international pharmaceutical company, where, as the Senior Vice President, and a member of both the Corporate Operating and Corporate Executive Committees, he made major contributions to the value of the company, which was acquired by Roche in 1994 for $5.3 billion.

Mr. Flanzraich was an early investor and member of the board of directors of Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director.  Mr. Flanzraich was the lead independent director of Equity One, Inc. (NYSE: EQY), prior to its acquisition by Regency Centers Corporation in 2017.  He was an independent director of Continucare Corporation (NYSE: CNU), a company with primary care centers, from 2002 to its sale in 2011.  Mr. Flanzraich received an AB from Harvard College and a JD from Harvard Law School.

Franz Hefti AlzheonChief Operating Officer, Proclara Biosciences

Franz Hefti, Ph.D. has served on our board of directors since April 2014. Dr. Hefti has also served as the Chief Operating Officer of Proclara Biosciences, Inc., a biotechnology company, since June 2015. Before that, Dr. Hefti served in senior managerial position at various biotechnology and pharmaceutical companies, including from November 2011 to January 2015 as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc., an AD diagnostic and therapy company, from January 2007 to December 2010 as Chief Scientific Officer of Avid Radiopharmaceuticals, Inc., a pharmaceutical company, from February 2003 to June 2006 as Executive Vice President of Rinat Neuroscience Corp., a biotechnology company, from September 1995 to December 2002 as Senior Vice President of Neuroscience Research at Merck & Co., a pharmaceutical company, and from January 1992 to August 1995 as Director of Neuroscience Research at Genentech Inc. a biotechnology company.

We believe that Dr. Hefti is qualified to serve on our board of directors because of his extensive experience in the pharmaceutical and biotechnology industries, particularly in AD.

Dennis Langer AlzheonClinical Professor, Georgetown University School of Medicine
Former Senior Vice President of Research and Development at GlaxoSmithKline

Dennis H. Langer, M.D. has served on our board of directors since February 2016. Dr. Langer also currently serves on the board of directors of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc. and Pernix Therapeutics Holdings, Inc. From January 2013 to July 2014 he served as Chairman and Chief Executive Officer of AdvanDx, Inc., a diagnostics company. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity and venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr. Reddy’s Laboratories, Ltd., a multinational pharmaceutical company. From September 1994 to January 2004, Dr. Langer held several leadership positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham, most recently as a Senior Vice President of Research and Development.

Dr. Langer has also, been a Clinical Professor, Department of Psychiatry at Georgetown University School of Medicine since 2003. Dr. Langer received his J.D. from Harvard Law School and his M.D. from Georgetown University School of Medicine.

We believe that Dr. Langer is qualified to serve on our board of directors because of his extensive experience in senior management positions in pharmaceutical and biotechnology companies, and his experience as a board member of various specialty pharmaceutical and biotechnology companies.

Scott Minick AlzheonVenture Partner, ARCH Venture Partners

Scott Minick has served on our board of directors since January 2014. Mr. Minick also serves on the board of directors of Chiasma, Inc. and as Executive Chairman of Aira Tech Corp., and has served as a Venture Partner of ARCH Venture Partners, a venture capital firm, since December 2008. From 2010 to 2015, Mr. Minick served on the board of directors and as the President and Chief Executive Officer of BIND Therapeutics, Inc., a pharmaceutical company or BIND.

Mr. Minick received his MBA from Northwestern University and postgraduate training in neurobiology at the Salk Institute.

We believe that Mr. Minick is qualified to serve on our board of directors because of his extensive business experience and his knowledge of the pharmaceutical and biotechnology industries.

David Nikodem AlzheonAlly Bridge Group

David P. Nikodem, Ph.D. was nominated to our board of directors by ABG II-Alzheon Limited, one of our shareholders, and has been a member of our board of directors since December 2014. Dr. Nikodem has also served as a senior representative of Ally Bridge Group, or ABG, and serves on the boards of several of ABG’s U.S.-based biopharmaceutical companies. From December 2010 to September 2013, Dr. Nikodem served as Portfolio Manager at Exane Asset Management, an asset management company, where he managed a global healthcare fund.

Dr. Nikodem received his Ph.D. in molecular biology from Georgetown University.

We believe that Dr. Nikodem is qualified to serve on our board of directors because of his investment experience and knowledge of the pharmaceutical and biotechnology industries.

Martin Tolar AlzheonFounder, President & Chief Executive Officer, Alzheon, Inc.

Prior to founding Alzheon in June 2013, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., where he led the development of human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., where he built the business for novel cancer therapeutics, and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he developed the first clinical-stage beta secretase inhibitor platform for Alzheimer’s disease and negotiated a collaboration with a potential value of $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings.

During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in Neurology at the Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease, and published many scientific publications in the area of neuroscience and neurodegenerative disorders. Dr. Tolar received his M.D. from Charles University in Prague, where as a medical student he helped organize and lead the Velvet Revolution that toppled the communist regime in the former Czechoslovakia in November 1989.

Dr. Tolar serves on business and scientific boards including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation and Advance Healthcare Management Institute.

Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017 and 2018.

We believe that Dr. Tolar is qualified to serve on our board of directors because of his scientific expertise and extensive experience in the pharmaceutical and biotechnology industries.